TY - JOUR
T1 - Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
AU - De Zeeuw, Dick
AU - Akizawa, Tadao
AU - Audhya, Paul
AU - Bakris, George L.
AU - Chin, Melanie
AU - Christ-Schmidt, Heidi
AU - Goldsberry, Angie
AU - Houser, Mark
AU - Krauth, Melissa
AU - Lambers Heerspink, Hiddo J.
AU - McMurray, John J.
AU - Meyer, Colin J.
AU - Parving, Hans Henrik
AU - Remuzzi, Giuseppe
AU - Toto, Robert D.
AU - Vaziri, Nosratola D.
AU - Wanner, Christoph
AU - Wittes, Janet
AU - Wrolstad, Danielle
AU - Chertow, Glenn M.
PY - 2013
Y1 - 2013
N2 - BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to
AB - BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to
UR - http://www.scopus.com/inward/record.url?scp=84890946148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890946148&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1306033
DO - 10.1056/NEJMoa1306033
M3 - Article
C2 - 24206459
AN - SCOPUS:84890946148
SN - 0028-4793
VL - 369
SP - 2492
EP - 2503
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 26
ER -